A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus
Latest Information Update: 16 Oct 2024
Price :
$35 *
At a glance
- Drugs Aminolevulinic acid/sodium ferrous citrate (Primary)
- Indications Diabetes mellitus; Mitochondrial disorders
- Focus Therapeutic Use
- 15 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2021 New trial record
- 12 Mar 2021 Trial design published in the Medicine